Home LiteratureArticle Details
PMID: 18301061 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Incidence and outcomes of malignancy in the HAART era in an urban cohort of HIV-infected individuals.

AIDS (London, England) ·Vol. 22 ·No. 4 ·2008-02-19 ·Pages 489-96

Long JL, Engels EA, Moore RD, Gebo KA

Abstract

To investigate trends, patient characteristics, and survival associated with AIDS-defining cancer (ADC) and non-AIDS defining cancer (NADC) in the HAART era. Retrospective analysis of all incident malignancies occurring in 1996-2005 among 2566 patients in an urban HIV clinic. Clinical profiles of NADC were compared with ADC and the general cohort. Incidence was examined by Poisson analysis. Standardized incidence ratios (SIR) compared cancer risk with that in the general population. Survival was analyzed by Kaplan-Meier and Cox proportional hazards models. Between 1996 and 2005, 138 ADC and 115 NADC were diagnosed. ADC rates decreased from 12.5 to 3.5 cases/1000 person-years (P < 0.001 for trend) while NADC rates increased from 3.9 to 7.1 cases/1000 person-years (P = 0.13 for trend). Incidence of the most common NADC was higher than expected, including cancers of the lung [n = 29; SIR, 5.5; 95% confidence interval (CI), 3.7-8.0], liver (n = 13, SIR, 16.5; 95% CI, 8.8-28.2), anus (n = 10; SIR, 39.0; 95% CI, 18.7-71.7), head and neck (n = 14; SIR, 5.1; 95% CI, 2.8-8.6), and Hodgkin's lymphoma (n = 8; SIR, 9.8; 95% CI, 4.2-19.2). Survival after cancer diagnosis did not differ between ADC and NADC. Advanced age was associated with NADC (P < 0.01 for trend) and increased mortality in ADC (age > or = 50 years adjusted hazard ratio, 2.21; 95% CI, 1.00-4.89). Rates of ADC decreased while NADC increased within this cohort. Several NADC occurred at rates significantly higher than expected. Screening and suspicion for NADC should increase in care for HIV-infected patients.

MeSH Terms
Adult Aged Antiretroviral Therapy, Highly Active Baltimore/epidemiology Epidemiologic Methods Female HIV Infections/complications,drug therapy,mortality Humans Male Middle Aged Neoplasms/complications,mortality Urban Health
Authors & Affiliations
4 authors, click to expand affiliations / ORCID
Long Jessica L
Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21287,USA.
Engels Eric A
Moore Richard D
Gebo Kelly A
References (30)
30 references, click to expand
  1. Trends in cancer risk among people with AIDS in the United States 1980-2002.
    AIDS. 2006 Aug 1;20(12):1645-54 PMID: 16868446
  2. Causes of death among human immunodeficiency virus (HIV)-infected adults in the era of potent antiretroviral therapy: emerging role of hepatitis and cancers, persistent role of AIDS.
    Int J Epidemiol. 2005 Feb;34(1):121-30 PMID: 15561752
  3. Cancer incidence in New York State acquired immunodeficiency syndrome patients.
    Am J Epidemiol. 2001 Sep 15;154(6):544-56 PMID: 11549560
  4. Combination antiretroviral therapy and recent declines in AIDS incidence and mortality.
    J Infect Dis. 1999 Mar;179(3):717-20 PMID: 9952385
  5. Cancer risk among participants in the women's interagency HIV study.
    J Acquir Immune Defic Syndr. 2004 Aug 1;36(4):978-85 PMID: 15220706
  6. Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy.
    J Natl Cancer Inst. 2005 Mar 16;97(6):425-32 PMID: 15770006
  7. HIV infection is associated with an increased risk for lung cancer, independent of smoking.
    Clin Infect Dis. 2007 Jul 1;45(1):103-10 PMID: 17554710
  8. AIDS and older Americans at the end of the Twentieth Century.
    J Acquir Immune Defic Syndr. 2003 Jun 1;33 Suppl 2:S68-75 PMID: 12853855
  9. Trends in causes of death among persons with acquired immunodeficiency syndrome in the era of highly active antiretroviral therapy, San Francisco, 1994-1998.
    J Infect Dis. 2002 Oct 1;186(7):1023-7 PMID: 12232845
  10. Use of flexible sigmoidoscopy to screen for colorectal cancer in HIV-infected patients 50 years of age and older.
    Arch Intern Med. 2006 Aug 14-28;166(15):1626-31 PMID: 16908796
  11. Immune deficiency and risk for malignancy among persons with AIDS.
    J Acquir Immune Defic Syndr. 2003 Apr 15;32(5):527-33 PMID: 12679705
  12. Statistical methods in cancer research. Volume II--The design and analysis of cohort studies.
    IARC Sci Publ. 1987;(82):1-406 PMID: 3329634
  13. Natural history of HIV infection in the era of combination antiretroviral therapy.
    AIDS. 1999 Oct 1;13(14):1933-42 PMID: 10513653
  14. Malignancy-related causes of death in human immunodeficiency virus-infected patients in the era of highly active antiretroviral therapy.
    Cancer. 2004 Jul 15;101(2):317-24 PMID: 15241829
  15. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults.
    MMWR Recomm Rep. 1992 Dec 18;41(RR-17):1-19 PMID: 1361652
  16. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators.
    N Engl J Med. 1998 Mar 26;338(13):853-60 PMID: 9516219
  17. Cancer risk in elderly persons with HIV/AIDS.
    J Acquir Immune Defic Syndr. 2004 Jul 1;36(3):861-8 PMID: 15213571
  18. AIDS malignancies in the era of highly active antiretroviral therapy.
    Oncology (Williston Park). 2002 Apr;16(4):441-51, 456, 459 PMID: 12017534
  19. Provision of general and HIV-specific health maintenance in middle aged and older patients in an urban HIV clinic.
    AIDS Patient Care STDS. 2006 May;20(5):318-25 PMID: 16706706
  20. Delayed diagnosis and elevated mortality in an urban population with HIV and lung cancer: implications for patient care.
    J Acquir Immune Defic Syndr. 2006 Sep;43(1):47-55 PMID: 16936558
  21. AIDS-related malignancies: changing epidemiology and the impact of highly active antiretroviral therapy.
    Curr Opin Infect Dis. 2006 Feb;19(1):14-9 PMID: 16374212
  22. Elevated incidence of lung cancer among HIV-infected individuals.
    J Clin Oncol. 2006 Mar 20;24(9):1383-8 PMID: 16549832
  23. Human papillomavirus-associated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome.
    J Natl Cancer Inst. 2000 Sep 20;92(18):1500-10 PMID: 10995805
  24. Pneumocystis jiroveci pneumonia prophylaxis is not required with a CD4+ T-cell count < 200 cells/microl when viral replication is suppressed.
    AIDS. 2007 Aug 20;21(13):1711-5 PMID: 17690568
  25. Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults.
    J Natl Cancer Inst. 2000 Nov 15;92(22):1823-30 PMID: 11078759
  26. Causes of death among persons with AIDS in the era of highly active antiretroviral therapy: New York City.
    Ann Intern Med. 2006 Sep 19;145(6):397-406 PMID: 16983127
  27. Incidence of non-AIDS-defining cancers before and during the highly active antiretroviral therapy era in a cohort of human immunodeficiency virus-infected patients.
    J Clin Oncol. 2003 Sep 15;21(18):3447-53 PMID: 12972519
  28. AIDS-related malignancies: emerging challenges in the era of highly active antiretroviral therapy.
    Oncologist. 2005 Jun-Jul;10(6):412-26 PMID: 15967835
  29. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study.
    J Acquir Immune Defic Syndr. 2006 Sep;43(1):27-34 PMID: 16878047
  30. Association of cancer with AIDS-related immunosuppression in adults.
    JAMA. 2001 Apr 4;285(13):1736-45 PMID: 11277828
Article Info
Journal
AIDS (London, England)
Abbr.
AIDS
ISSN
1473-5571
Published
2008-02-19
Pages
489-96
Language
English
Region
England
NLM ID
8710219
PMCID
PMC2553213
Subset
IM
Grants
NIDA NIH HHS · R01 DA011602 · United States
NIDA NIH HHS · K23 DA000523 · United States
NIDA NIH HHS · R01-DA-11602 · United States
NIDA NIH HHS · K24-DA00432 · United States
NIDA NIH HHS · K24 DA000432-09 · United States
NIDA NIH HHS · K23-DA00523 · United States
NIAAA NIH HHS · R01 AA016893 · United States
NIDA NIH HHS · R01 DA011602-10 · United States
NIDA NIH HHS · K24 DA000432 · United States
NIDA NIH HHS · U01 DA036935 · United States
NIA NIH HHS · R01 AG026250 · United States
NIAID NIH HHS · U01 AI069918 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]